Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia. Issue 7 (7th June 2022)

• Record Type: Journal Article
• Authors: Graveno, Molly E.; Carulli, Alison; Freyer, Craig W.; Mangan, Brendan L.; Nietupski, Robert; Loren, Alison W.; Frey, Noelle V.; Porter, David L.; Gill, Saar I.; Hexner, Elizabeth O.; Luger, Selina M.; Martin, Mary Ellen; McCurdy, Shannon R.; Perl, Alexander E.; Babushok, Daria V.; Pratz, Keith W.
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 7(2022)
• Page Start: 1645
• Page End: 1650
• Publication Date: 2022-06-07
• Subjects: Relapsed/refractory AML -- venetoclax -- hypomethylating agent -- low-dose cytarabine; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2042688
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Limited treatment options exist for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Venetoclax (VEN) in combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) has been recently approved for treatment-naïve patients unfit for intensive induction. Limited data are available to characterize the efficacy of VEN combinations in R/R AML. We retrospectively analyzed 77 patients with a median of 1 prior therapy (range 0–5) treated with VEN combinations for R/R AML or AML secondary to myelodysplastic syndrome (MDS) progressing after HMA monotherapy. The median overall survival (OS) was 13.1 months (95% CI 9.2–15.1). The median progression-free survival (PFS) was 12 months (95% CI 8.2–15.4) with a median duration of response of 8.9 months (95% CI 5.7–13.9). Overall response rate (ORR) was 68% with a composite complete response (CR) and CR with incomplete hematologic recovery (CRi) rate of 53%. VEN combination therapy is efficacious in R/R AML and further prospective studies are warranted.